Background and purpose: New venues are currently being explored to predict disease progression in Parkinson's disease (PD), such as non-motor subtypes and models merging motor and non-motor symptoms (NMS). By involving a subgroup of 585 patients from the PRIAMO (Parkinson Disease Non-motor Symptoms) study, the present 24-month longitudinal prospective analysis aimed to demonstrate that urinary dysfunction is an early marker of higher motor and non-motor burden as well as lower health-related quality of life. Methods and results: Multivariable mixed-effect logistic regression models controlling for demographic and clinical variables showed that the following NMS domains were associated with urinary dysfunction: gastrointestinal [odds ratio (OR) 2.57, 95% confidence interval (CI) 1.67-3.97, P < 0.001], cardiovascular (OR 2.22, 95% CI 1.18-4.17, P = 0.013), skin (OR 1.81, 95% CI 1.06-3.08, P = 0.029), sleep (OR 2.06, 95% CI 1.34-3.16, P = 0.001), pain (OR 1.85, 95% CI 1.21-2.83, P = 0.004), fatigue (OR 2.40, 95% CI 1.56-3.68, P < 0.001), apathy (OR 2.79, 95% CI 1.72-4.52, P < 0.001) and respiratory (OR 1.82, 95% CI 1.02-3.23, P = 0.039). Analysis also demonstrated that urinary dysfunction was associated with higher motor disability (coefficient 1.73, 95% CI 0.68-2.78, P = 0.001) and lower health-related quality of life (coefficient À0.05, 95% CI À0.08 to À0.02, P < 0.001, and coefficient À3.49, 95% CI À5.21 to À1.77, P < 0.001) but not with more severe cognitive disability (coefficient À0.34, 95% CI À0.92 to 0.24, P = 0.251). Conclusions: This is the first prospective longitudinal study involving a large cohort of PD patients demonstrating the relevance of urinary dysfunction as an early marker of higher motor and non-motor disability as well as lower health-related quality of life. These findings support a role for urinary dysfunction as an early marker of more severe disease progression.
Introduction
According to prevalence studies, urinary dysfunction is present in 30%-65% of patients with Parkinson's disease (PD), being significantly more frequent than in healthy controls [1] . Urinary symptoms (US) in PD include nocturia, urgency, frequency, incontinence and difficulty in voiding, all attributable to bladder overactivity and thought to reflect an alteration in frontalbasal ganglia circuits that normally suppress the micturition reflex [2] [3] [4] [5] . US may occur from the premotor phase of PD and are associated with higher motor disability, more severe dopaminergic denervation and poorer quality of life [6] [7] [8] [9] [10] [11] .
The complexity of phenotypes and the pathophysiology of PD cannot be entirely depicted considering motor symptoms alone; thus, new venues are currently being explored and novel classifications anchored to non-motor symptoms (NMS) and/or models merging motor and non-motor symptoms have been proposed to predict disease progression [12] [13] [14] [15] [16] . In this scenario, NMS act as clinical biomarkers foreseeing disease trajectory and thus may represent valuable markers in neuroprotection clinical trials. Accordingly, it was recently demonstrated that the presence of US features a subgroup of de novo PD patients who are more prone to manifest a rapid functional decline, as demonstrated by an increased likelihood to be started on L-dopa therapy, irrespective of gender, age and motor features [17] . However, little is known about the natural history of early PD patients with urinary dysfunction.
By further analysing prospective data from a subset of patients of the PRIAMO (Parkinson Disease Nonmotor Symptoms) study [18] , the present work aims to demonstrate that urinary dysfunction identifies a subgroup of PD patients with worse prognosis in terms of motor and non-motor disability. In detail, the goals were to evaluate whether urinary dysfunction (i) associates with other NMS and (ii) is a marker of higher motor and cognitive disability as well as lower quality of life. Finally, the results of a detailed semi-structured interview focused on a variety of US are reported.
Patients and methods

Patients and assessments
This study involves a subgroup of patients from the PRIAMO study. The PRIAMO study is a large Italian multicentre observational study, including a crosssectional and a longitudinal prospective 24-month phase, designed to assess the prevalence and evolution of NMS in patients affected by different parkinsonian syndromes [19, 20] .
The study methods and patient baseline features have been extensively described elsewhere [19, 20] . Each patient underwent a baseline (T1) and two follow-up visits, at 12 months (AE4) after the baseline visit (T2) and 9-16 months after the first follow-up visit (T3), respectively. The diagnosis of idiopathic PD was based on the Gelb et al. [21] criteria. PD-associated urinary dysfunction was evaluated with a clinician rated questionnaire and was defined by the presence of at least one of the following symptoms: (i) urgency; (ii) frequency (need of voiding every 2 h or less); (iii) nocturia. Furthermore, patients were administered a semi-structured interview exploring 11 other NMS domains (gastrointestinal, pain, cardiovascular, sleep, fatigue, apathy, attention/memory, skin, psychiatric, respiratory and other symptoms including smell and taste impairment, diplopia, weight change and sexual disturbances), each one including 2-10 specific questions with dichotomous (yes/no) answers (Data S1) [19] .
The Unified Parkinson's Disease Rating Scale À part III (UPDRS-III) was used to evaluate motor disability, whilst cognitive abilities were investigated with the Mini-Mental State Examination (MMSE). Healthrelated quality of life (HRQoL) was investigated using the EuroQol 5-Dimension (EQ-5D) and the EuroQol Visual Analogue Scale (EQ-VAS) [22] . All these scales are available for the Italian population.
In addition, only patients reporting urinary dysfunction in the PRIAMO clinician rated questionnaire were administered a modified version of the American Urological Association Symptom Index [23] , specifically investigating the occurrence of several US during the past month (Data S1). All the clinicians involved were expert in movement disorders and participated in a training session before starting enrolment for the PRIAMO study.
For this subanalysis, only patients with early stage PD [namely, Hoehn and Yahr (H&Y) stage ≤2] at baseline and with no missing answers to questions related to US in the clinician rated questionnaire for at least two assessments were considered. The study was approved by the ethics committees of the participating centres and all patients provided written informed consent.
Statistical analysis
Of 1142 PD patients enrolled in the PRIAMO study, 585 PD patients had H&Y stage ≤2 at baseline and with no missing answers in the questions evaluating urinary dysfunction in the clinician rated questionnaire for at least two assessments and thus were eligible for the present study. The included subjects were divided into PD with (PD-UD) and PD without (PD-NUD) urinary dysfunction over a follow-up of 24 months and were confronted for demographics and clinical assessments.
After checking the normal distribution of variables, comparisons between groups were performed using chi-squared, the t test and analysis of variance (ANOVA) as appropriate. Accordingly, descriptive statistics are presented as proportions or mean and standard deviation (SD). In order to test a possible association between NMS and PD-associated urinary dysfunction (i.e. the outcome) over time multivariable mixed-effect logistic regression models were computed controlling for gender, age, age at onset and disease duration, UPDRS-III and L-dopa treatment. To test whether urinary dysfunction mirrors motor and cognitive disability and HRQoL, multivariable mixed-effect linear regression models were used, considering UPDRS-III, MMSE, EQ-5D and EQ-VAS as outcome variables and gender, age, age at onset, disease duration and L-dopa treatment as covariates. All covariates used for the adjusted analyses were tested for multicollinearity. The multicollinearity diagnostics (variance inflation factor) were all less than 5, indicating an assumption of reasonable independence amongst predictor variables. Results are presented as adjusted odds ratio (OR) and regression coefficients, as appropriate, and 95% confidence intervals (95% CI) and were considered statistically significant for P ≤ 0.05. Statistical analyses were performed with STATA software (version 14.0; Stata-Corp LP, College Station, TX, USA).
Results
Demographic and clinical features of the included cohort at T1, T2 and T3 are displayed in Table 1 . The prevalence of urinary dysfunction was stable all over the longitudinal phase (from 49.06% at T1 to 51.74% at T3), whilst 12-and 24-month incidences were 11.6% and 8.0%, respectively.
PD-UD were older, more frequently men and with higher UPDRS-III compared to PD-NUD. Moreover, at T3 PD-UD were more frequently on L-dopa and had lower MMSE scores than PD-NUD. As for NMS, all domains were more frequently affected in PD-UD at all visits (Table 1) .
Multivariable mixed-effects logistic models showed that the following NMS domains were more likely to be associated with urinary dysfunction: gastrointestinal (OR 2.57, 95% CI 1.67-3.97, P < 0.001), cardiovascular (OR 2.22, 95% CI 1.18-4.17, P = 0.013), skin (OR 1.81, 95% CI 1.06-3.08, P = 0.029), sleep (OR 2.06, 95% CI 1.34-3.16, P = 0.001), pain (OR 1.85, 95% CI 1.21-2.83, P = 0.004), fatigue (OR 2.40, 95% CI 1.56-3.68, P < 0.001), apathy (OR 2.79, 95% CI 1.72-4.52, P < 0.001) and respiratory (OR 1.82, 95% CI 1.02-3.23, P = 0.039).
Multivariable mixed-effects linear models showed that urinary dysfunction was associated with higher motor disability (coefficient 1.73, 95% CI 0.68-2.78, P = 0.001) (Fig. 1a) and lower HRQoL (EQ-5D, coefficient À0.05, 95% CI À0.08 to À0.02, P < 0.001; EQ-VAS, coefficient À3.49, 95% CI À5.21 to À1.77, P < 0.001) but not with more severe cognitive disability (coefficient À0.34, 95% CI À0.92 to 0.24, P = 0.251) (Fig. 1b) .
The results of the modified version of the American Urological Association Symptom Index administered to PD-UD are shown in Fig. 2 and in Data S1.
Discussion
This is the first prospective longitudinal study involving a large cohort of PD patients demonstrating the relevance of urinary dysfunction as an early marker of higher motor and non-motor disability as well as lower HRQoL.
In line with previous evidence [1] , our cohort of early PD patients presented a prevalence of urinary dysfunction of approximately 50%, which remained stable during the observation period. Accordingly, the incidence of US at both T2 and T3 was relatively low (11.6% and 8.0%, respectively), suggesting that urinary dysfunction occurs very early and its frequency remains stable through the initial phase of the disease. Urgency, nocturia and frequency (i.e. storage symptoms) were the most common US, followed by weak urinary stream, incomplete bladder emptying and incontinence episodes (i.e. voiding symptoms) [24] . Normal urinary storage is dependent on the sacral autonomic reflex as well as the spino-bulbo-spinal autonomic reflex, which are controlled by the midbrain and pontine nuclei, the basal ganglia and the frontal cortex [2] . In PD, the disruption of the frontal cortexÀbasal ganglia circuits is thought to cause bladder overactivity, thus resulting mainly in storage symptoms [24] . Each of the US remained stable except urgency and nocturia which showed a mild increase over the follow-up (Fig. 2) , further supporting the early impairment of the autonomic reflexes in the course of the disease.
The most novel finding of our analysis was that, irrespective of disease severity as evaluated with the H&Y, PD-UD displayed distinctive demographic and clinical features compared to PD-NUD [12] .
Confirming previous studies using either questionnaires or urodynamic tests [11, 25] , PD-UD subjects were more frequently men and older at the time of the assessments compared to PD-NUD. On the other hand, urinary dysfunction was not linked to age at onset further suggesting that it might truly reflect the severity of disease irrespective of disease duration [10] . As for clinical features, urinary dysfunction was associated with greater motor disability and increasing L-dopa treatment rate over the longitudinal phase, reflecting a faster motor impairment and disease progression of PD-UD (Fig. 1a) [17] . In addition, by analysing data from a large dataset, it was confirmed that PD-UD complain of a higher number of NMS compared to PD-NUD, supporting a role for urinary dysfunction as a marker of both motor and non-motor disability [17] . Intriguingly, several NMS domains associated with urinary dysfunction were found, namely gastrointestinal, cardiovascular, skin, sleep, pain, fatigue, apathy and respiratory. The aggregation of a variety of autonomic symptoms including urinary, gastrointestinal (i.e. constipation), cardiovascular (i.e. postural hypotension) and skin (i.e. excessive sweating) disturbances is not entirely surprising and supports the existence of a 'Park autonomic subtype' of the disease, a broad definition classifying a group of PD patients with dominant autonomic dysfunction from the earliest stages [12] . Indeed, our Fifty-one patients (9.2%) were lost at T3. findings are in line with previous data suggesting that autonomic dysfunction appears in the earliest phase of the disease and, as such, should be considered as a risk factor for PD development or severer progression in PD patients [12, 26, 27] . A body of evidence shows that US may foresee incident PD in community-dwelling older adults [9, 28] . Accordingly, neuropathological studies report pathological findings in the sacral and thoracic segments of the spinal cord as well as the paravertebral sympathetic ganglia in 70%-100% of cases of incidental Lewy body disease (i.e. autoptic cases of Lewy-related pathology but without a clinical history of parkinsonism) [29] . The coexistence of urinary dysfunction with sleep disorders is consistent with the brainstem involvement early in the course of the disease demonstrated by neuropathological studies [12, 30] . On the other hand, the association with pain, fatigue, apathy and respiration symptoms (i.e. dyspnoea) may be explained in the light of a more diffuse involvement of the central nervous system in these patients [31] . Alternatively or complementarily, the higher prevalence of motor fluctuations in PD-UD compared to PD-NUD (14.28% vs. 5.70%, P < 0.001) may also account for the higher prevalence of NMS in PD-UD [32] . Confirming previous data [11] , it was shown that US have a detrimental effect on HRQoL. This finding is in line with a robust body of evidence demonstrating that HRQoL in PD mainly relies on non-motor burden [20, 33] .
Regarding cognition, although there is a trend for lower MMSE in PD-UD as the disease progresses (Fig. 1b) , the regression analysis failed to detect a significant association between urinary dysfunction and cognitive deterioration. The low sensitivity of the MMSE as well as the lack of further cognitive tests may account for this finding and prevent firm conclusions being drawn on this point.
The present data further support the concept that H&Y as well as all the motor assessments alone are insufficient to subtype PD patients, highlighting the need for more comprehensive instruments, including both motor and non-motor features for foreseeing disease progression [14] . Complementarily, our data represent an argument in favour of recent proposals for the non-motor subtyping of PD patients [12, 13] . In this scenario, urinary dysfunction is proposed as a marker capable of envisaging disease trajectory and thus possibly representing a valuable variable in neuroprotection clinical trials.
Our study has limitations. First, the lack of a longer longitudinal phase precludes the possibility of describing the complete natural history of PD patients with urinary dysfunction. Notwithstanding, this is the largest study to date evaluating prospectively both motor and non-motor burden in patients with urinary dysfunction compared to those without. Secondly, it is recognized that a small proportion of the baseline cohort might be contaminated by multiple system atrophy cases as urinary dysfunction early in the course of the disease should alert the clinician toward this diagnosis [34] . However, this bias should have been minimized as more than 90% of patients were reassessed after 24 months since baseline and PD diagnosis was confirmed in all of them. Furthermore, the presence of urinary tract infections may in part account for certain US. Although culture data were not available in our population, during the clinical interview patients were asked to report on the presence of symptoms suggestive of urinary tract infections such as burning with urination, haematuria, malodorous urine and cystitis over the previous month. In PD-UD, burning with urination was present in 10.06% at T1, 10.04% at T2 and 8.49% at T3; haematuria was reported by 1.33% at T1, 0.84% at T2 and 0.94% at T3; malodorous urine was described by 8.85% at T1, 8.37% at T2 and 9.91% at T3; cystitis was reported by 10.45% at T1, 11.55% at T2 and 10.25% at T3. Our analysis was repeated excluding these subjects and results were confirmed (data not shown). Indeed, it cannot be excluded that urinary tract infections have a role in determining certain US in PD; however, it is unlikely that they represent a significant source of bias in our study, given also the 2-year longitudinal follow-up. Finally, the lack of a control group from the general population represents another drawback as urinary dysfunction may be experienced by the general population as well. However, several caseÀcontrol studies have already shown that US are more prevalent in PD patients compared to healthy controls [1, 2] . In addition, the large sample size of our study should attenuate this bias.
In conclusion, our 24-month longitudinal prospective study showed that urinary dysfunction is a marker of higher motor and non-motor burden and worse disease progression in early PD. Specific NMS associate with urinary dysfunction, mainly gastrointestinal, cardiovascular, skin and sleep disturbances. These findings support a role for urinary dysfunction as a marker of disease progression and constitute arguments in favour of non-motor subtyping of PD patients.
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